Quanterix Corporation has announced changes to its Board of Directors following the acquisition of Akoya Biosciences. Scott Mendel and Myla Lai-Goldman, MD, have been appointed to the board, replacing Martin D. Madaus, PhD, and Sarah Hlavinka. Masoud Toloue will continue as Chief Executive Officer, and Vandana Sriram will remain as Chief Financial Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250707828058) on July 08, 2025, and is solely responsible for the information contained therein.
Comments